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Abstract
Multiple reports have claimed that low-dose orally administered interferon (IFN)-a is beneficial in the treatment of
many infectious diseases and provides a viable alternative to high-dose intramuscular treatment. However, research
is needed on how to express IFN stably in the gut. Bifidobacterium may be a suitable carrier for human gene
expression and secretion in the intestinal tract for the treatment of gastrointestinal diseases. We reported
previously that Bifidobacterium longum can be used as a novel oral delivery of IFN-a. IFN-transformed B. longum
can exert an immunostimulatory role in mice; however the answer to whether this recombinant B. longum can be
used to treat virus infection still remains elusive. Here, we investigated the efficacy of IFN-transformed B. longum
administered orally on coxsackie virus B3 (CVB3)-induced myocarditis in BALB/c mice. Our data indicated that oral
administration of IFN-transformed B. longum for 2 weeks after virus infection reduced significantly the severity of
virus-induced myocarditis, markedly down regulated virus titers in the heart, and induced a T helper 1 cell pattern
in the spleen and heart compared with controls. Oral administration of the IFN-transformed B. longum, therefore,
may play a potential role in the treatment of CVB3-induced myocarditis.
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Introduction
The oral use of low doses of interferon (IFN)-a has
been shown to exhibit beneficial effects in mice or
human with acquired immunodeficiency syndrome
(AIDS) [1], hepatitis B [2], aphthous stomatitis [3], and
measles [4]. These studies have indicated that IFN-a/-b
given orally provides a viable alternative to the current
high-dose treatment intramuscularly [5,6]. The number
of dairy and probiotic products that contain bifidobac-
teria has developed rapidly in recent years, and its pro-
biotic properties have been extended further by the
production of the recombinant Bifidobacterium-contain-
ing products [7-11]. Genetically engineered Bifidobacter-
ium has been reported as a successful exogenous gene
delivery carrier for the treatment of many diseases. We
previously constructed a recombinant B. longum (IFN-
transformed B. longum) that was inducible by arabinose
to express efficiently secreted IFN-a2b in vitro [12].
Moreover, oral administration of IFN-transformed B.
longum to mice increased intestinal sIgA and serum
IFN-a2b levels, which suggested the potential clinical
value of this bacterium as a kind of oral interferon in
the treatment of virus infection [13].
Human IFN can inhibit coxsackievirus B3 (CVB3)
replication in vitro and protects murine models from
CVB3-induced myocarditis [14-19]. However, it is not
clear whether oral administration of IFN can treat
CVB3-induced myocarditis in vivo.I nt h i ss t u d y ,t h e
effect of IFN-transformed B. longum by oral administra-
tion on the development of CVB3-induced myocarditis
in mice was evaluated.
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Cells and viruses
CVB3 (Nancy strain) was obtained from Prof. Wang at
the Department of Biotechnology of Ginan University,
China [20]. African green monkey kidney (Vero) cells
were cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) that contained 8% fetal calf serum (Gibco,
Rockville, USA). Confluent cultures of Vero cells were
infected with CVB3 and incubated at 37°C until an
extensive cytopathic effect was observed (generally at 3-
5 days post-infection). Subsequently, the culture media
were collected, the cell debris was pelleted by centrifu-
gation and removed and the supernatant was aliquoted
and stored at-80°C.
Bacteria culture
IFN-transformed B. longum were constructed by trans-
forming B. longum with pBAD-SPIFN (BSPIFN) as
reported [12]. Briefly, BSPIFN plasmids consisted of a
fusion gene of the arabinosidase signal peptide and
human IFN-a2b (hIFNa2b). Recombinant IFN-trans-
formed B. longum contained an L-arabinose promoter
and displayed highly efficient IFN-a2b expression [12].
The control plasmid-transformed B. longum bacteria
were transformed with the control plasmid (pBAD-
gIIIA) without the insertion of hIFN-a2b gene. Recom-
binant BSPIFN- and control plasmid-transformed B.
longum were cultured anaerobically and prepared as
described in our previous report [12]. A 10-μls u s p e n -
sion of bacteria was seeded onto BL agar plates (Nissui)
that contained 100 g L
-1 ampicillin to determine the
actual number of viable bacilli in the inocula. Colonies
were counted after 24 h of anaerobic culture.
Interventions and groups
This study was approved by the Ethics Committee of
Southern Medical University (Guangzhou, China). Four-
week-old male BALB/c mice (weight, 15 ± 0.5 g; South-
ern Medical University, USA) were inoculated i.p. with a
50% cell-culture infectious dose of CVB3 at 5 × 10
6 (as
determined by plaque assay on Vero cells). Infected ani-
mals given this virus dosage survived for at least 6
months post-infection. We studied the efficacy of IFN-
transformed B. longum on coxsackievirus B3-induced
myocarditis. Forty BALB/c mice were inoculated with
the virus and were divided into four groups. ‘BIFN’
group and ‘Control’ group animals were administered
orally with IFN- and control plasmid- transformed B.
longum for 2 weeks respectively after the inoculation of
the virus. The ‘IFN’ group was injected i.m. with a ther-
apeutic dose (1.5 μgk g
-1w e e k
-1) of pegylated IFN a2b
(PegIntron). The ‘saline’ group was administered i.p.
once daily with sterile saline after infection. Three mice
were kept under the same conditions to act as the nor-
mal control. Recombinant bacteria were given to the
mice orally once every 2 days using a tuberculin syringe
attached to a 20-gauge olive-tip steel feeding tube,
passed through the oral cavity and esophagus. All ani-
mals were killed at day 14 post-infection (following
ether anesthesia). Up to day 14 post-infection, half of
the murine hearts were dissected aseptically for virus
titration and RNA extraction for cytokine quantity. The
other half of the heart was used for hematoxylin-eosin
(H&E) staining. The spleen was removed surgically to
isolate mononuclear cells (MNCs).
Morphometry
Hematoxylin-eosin staining was performed according to
the standard techniques. The selected surfaces of myo-
carditis lesions studied were considered to be represen-
tative of the relative inflammatory area in the entire
heart volume, because of the relatively homogeneous
distribution of the myocarditis lesions in the affected
hearts. The number of myocarditis lesions and their sur-
face proportion were determined with H&E-stained sec-
tions of the hearts of the untreated and other groups.
The proportion of the surface occupied by myocarditis
lesions was determined by means of a conventional
point-counting method, as reported earlier [21], by
using an ocular grid that contained 121 equally spaced
points. The surface proportion was taken to be an esti-
mate of the percentage of heart tissue that was affected
by focal myocarditis. Counting was performed on three
sections per heart and the sections were evaluated at a
magnification of less than ×200.
Virus titration from heart homogenate
The aseptic hearts of the animals were weighed and
homogenized in the minimal essential medium of 2 ml
phosphate-buffered saline (PBS). The supernatant was
subjected to three freeze-thaw cycles and centrifugation
at 5000 rpm for 8 min, then was absorbed and diluted
sequentially 10-fold in RPMI 1640 medium. Vero cells
were grown to confluence in microtiter trays, infected
with serial dilutions of the homogenates, and incubated
for 3 h at 37°C. The cells were cultured for 72 h of cul-
tivate, then the monolayers were fixed in 10% phos-
phate-buffered formalin and stained with crystal violet
(Invitrogen); the numbers of plaques were counted.
Virus titers were determined by standard plaque forma-
tion assay and expressed as per organ weight (in grams).
Quantitation of transcript level of cytokines and Mx1
The total RNA of the heart tissues was extracted with
Trizol reagent (Invitrogen, Carlsbad, CA, USA) and
reverse transcribed into cDNA according to the
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USA). Transcription of IFN-g,T N F - a,M x 1o rt h e
housekeeping gene b-actin was detected by real-time
polymerase chain reaction (PCR) using a SYBR Green
Master Mix (Applied Biosystems). Thermocycler condi-
tions included an initial denaturation step at 94°C for 2
min; a three-step cycle procedure was carried out (dena-
turation, 94°C, 20 s; annealing, 58°C, 20 s; and exten-
sion, 72°C, 30 s) for 35 cycles. All reactions were
performed in at least duplicate for each sample. Data
were collected and analyzed quantitatively on an ABI
Prism 7900 sequence detection system (Applied Biosys-
tems). The b- a c t i ng e n ew a su s e da sa ne n d o g e n o u s
control to normalize for differences in the amount of
total RNA in each sample and the relative mRNA
expression was calculate by normalization to the value
of the b-actin transcripts. Primers for IFN-g,T N F - a,
Mx1 and the housekeeping gene b-actin have been
reported previously [13,21].
Preparation of mononuclear cells (MNCs) and cytokine
detection
Spleens were removed surgically, and the MNCs were iso-
lated as described previously [22]. Suspensions of MNCs
from the spleen were prepared with RPMI-1640 culture
medium that contained heat-inactivated fetal bovine
serum (50 mL L
-1), L-glutamine (2 mM), penicillin (1 ×
10
5 UL
-1), streptomycin (100 mg L
-1), and HEPES (25
mM) (all from Life Sciences). The MNCs were seeded into
24-well plates (each well had 2 × 10
8 cells L
-1) and stimu-
lated subsequently with 100 μLo fC o nA( 5m gL
-1) for 72
h at 37°C, 5% CO2 in air, and 95% humidity. The levels of
IFN-g,T N F - a and IL-10 in the supernatants were mea-
sured by OptEIA commercial enzyme-linked immunosor-
bent assay (ELISA) kits (BD Pharmingen), following the
manufacturers’ instructions. The detection limits of the
ELISA assays were as follows: 2500 pg ml
-1 for IFN-g, 825
pg ml
-1 for TNF-a and 650 pg ml
-1 for IL-10.
Statistical analysis
Data were shown as the mean ± standard error of the
mean (SEM). Statistical analyses of the data were per-
formed by one-way analysis of variance (ANOVA), and
the correlation between two variables was tested by
bivariate correlation analysis using SPSS11.0; a p-value <
0.01 was considered to be statistically significant.
Results
Evaluations for the severity of myocarditis and virus
replication
The prominent cardiac inflammation area is observed in
Figure 1. The percentage of the pathological area of the
heart sections in the BIFN, B, IFN-a and saline groups
was elevated and is compared in Figure 2a. The patholo-
gical area of heart sections in the BIFN group was sig-
nificantly lower compared with the B and saline groups
(p < 0.01) respectively, but markedly high compared
with the IFN group. The levels of cardiac CVB3 titers
and CVB3 RNA in the cardiac tissues of the BIFN
group were significantly lower compared with the B and
saline groups respectively and markedly higher com-
pared with IFN group (p < 0.01) (Figure 2b).
A  B 
D E 
C 
Figure 1 Evaluation of the severity of myocarditis.( a-e) are representative of histopathologic images in heart tissue from saline, B, BIFN and
interferon (IFN) groups respectively (hemotoxylin and eosin (H&E) staining, original magnification × 200). Ten mice per group were analyzed in
this study.
Yu et al. Virology Journal 2011, 8:525
http://www.virologyj.com/content/8/1/525
Page 3 of 6Saline B BIFN IFN
0.0
0.1
0.2
0.3
0.4
0.5
**
*
*
*
A
R
e
l
a
t
i
v
e
 
i
n
f
l
a
m
m
a
t
o
r
y
 
a
r
e
a
Saline B BIFN IFN
0
1
2
3
4
5
6
**
*
*
*
B
C
V
B
3
 
t
i
t
e
r
s
Saline B BIFN IFN
0.0
0.4
0.8
1.2
1.6
2.0
**
*
*
*
C
r
e
l
a
t
i
v
e
 
I
F
N
-
¦
Ã
m
R
N
A
 
r
e
s
u
l
t
Saline B BIFN IFN
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
**
*
*
*
D
R
e
l
a
t
i
v
e
 
T
N
F
-
¦
Á
m
R
N
A
 
r
e
s
u
l
t
Saline B BIFN IFN
0
250
500
750
1000
1250
1500
1750
*
*
*
**
E
I
F
N
-
¦
Ã
(
p
g
/
m
l
)
Saline B BIFN IFN
0
100
200
300
400
**
*
*
*
F
T
N
F
-
¦
Á
(
p
g
/
m
l
)
Saline B BIFN IFN
0
40
80
120
160
200
240
**
*
*
*
G
I
L
-
1
0
(
p
g
/
m
l
)
Saline B BIFN IFN
0.0
0.5
1.0
1.5
2.0
2.5
**
*
*
*
H
R
e
l
a
t
i
v
e
 
M
x
1
 
m
R
N
A
 
r
e
s
u
l
t
Figure 2 Pathological areas of the heart. The percentage of pathological areas in different groups was shown in (a). The coxsackievirus B3
(CVB3) titration detected by standard plaque formation assay was indicated in (b). The levels of interferon (IFN)-g and tumor necrosis factor
(TNF)-a mRNA were determined in (c) and (d) respectively. The concentration of, IFN-g and TNF-a and were shown in (e, f and g) respectively.
The detection of IFN-induced Mx1 mRNA was determined in (h). **versus B group, p> 0.05; *versus BIFN group, p < 0.01.
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We evaluated the T helper (Th) cell patterns induced by
oral-administered IFN-transformed B. longum by mea-
surement of the levels of two typical Th1 cytokines
(IFN-g and TNF-a). Our data showed that the cardiac
IFN-g and TNF-a mRNA levels in the BIFN group were
enhanced significantly compared with that in the saline
and B groups but were markedly reduced compared
with that in the IFN-a group (p < 0.01; Figure 2c, d).
Furthermore, we detected the levels of IFN-g,T N F - a
and IL-10 in the supernatant from the cultured MNCs
from murine spleen. The levels of supernatant IFN-g
and TNF-a in the BIFN group were markedly raised
compared with that in the saline and B groups (p <
0.01). Moreover, the levels of serum IL-10 in BIFN
group were also markedly decreased compared with that
in the saline and B groups (p < 0.01; Figure 2g).
Increased expression of Mx1 mRNA in cardiac tissues
The Mx1 gene is induced typically by IFN. Its intracellular
gene transcription level in a tissue samples can represent
the relative amount of local type I IFN that stimulates the
cells or tissues [23,24]. We measured the Mx1 gene tran-
scription levels in cardiac tissues using real-time PCR to
evaluate the local type I IFN concentration and activity.
High Mx1 mRNA transcript levels were detected in the
BIFN group compared with the saline and B groups respec-
tively (p < 0.01; Figure 2h), a finding that was suggestive of
a possibly high type I IFN concentration in this organ.
Discussion
In this experiment, we proved the efficacy of the BIFN-
transformed B. longum cells on the CVB3-induced myo-
carditis. Oral administration of IFN-transformed B.
longum cells can reduce significantly the cardiac inflam-
matory area of CVB3-infected mice by day 14 compared
with the B and saline groups respectively, which suggested
that BIFN-transformed B. longum cells can improve the
severity of disease. It has been demonstrated that the
dominant pathogenic process in the early stages of CVB3
infection is the direct attack on myocardial cells by the
virus, therefore antivirus treatment at this phase is very
important to improve the development of virus infection
[25]. Our data indicated that the cardiac virus titers in the
murine heart of BIFN group were decreased significantly
compared with B group, which indicated that this recom-
binant B. longum may improve cardiac inflammation
partly by inhibition of virus replication at the early stage of
CVB3 infection. Classical theories suggest that CD4
+ Th1
c e l l sp l a yav i t a lr o l ea g a i n s tvirus infection in adaptive
immune responses by production of IFN-g for effective
clearance of virus invasion. In this study, IFN-transformed
B. longum increased the expression of Th1 cytokines
(IFN-g and TNF-a) mRNA in cardiac tissue and enhanced
the secretion of Th1 cytokines (IFN-g and TNF-a)f r o m
splenocytes, which suggested that this recombinant B.
longum is able to induce expression of CD4
+ Th1 cells
against virus infection.
O u rf o r m e rs t u d i e sh a v es h o w nt h a th I F N - a2b from
IFN-transformed B. longum is expressed mainly as a
mature secretory cytokine and that serum hIFN-a2b
level can be enhanced in the mice that have been admini-
strated orally with B. longum [12,13]. As we know, the
expression of hIFN-a2b in IFN-transformed B. longum is
mainly induced by L-arabinose, which is a component of
biopolymers such as hemicellulose and pectin [26]. The
administration of IFN-transformed B. longum has been
demonstrated to increase the serum and intestinal IFN-
a2b level and we hypothesize that IFN expression by this
bifidobacteria in mice might be induced persistently by
L-arabinose in MRS or by the administered food and
then enter the blood circulation by gastrointestinal
absorption [13]. In this study, we compared mice either
treated with saline and control B. longum mice respec-
tively. The Mx1 mRNA levels, which represent the local
tissue IFN concentration, were increased significantly in
cardiac tissues in the BIFN group, which suggested that
IFN-transformed B. longum can increase the level of
active type 1 IFN locally. Further study is needed to
ascertain how to control the expression of IFN stably in
gut and whether these bacteria affect the microbial flora.
Bifidobacterium has many beneficial effects on human
health that include prevention of infection, immunomo-
dulation, promotion of lactose digestion and protection
against colon cancer [9-11]. Recently, genetically engi-
neered Bifidobacterium has been used successfully as an
exogenous gene delivery carrier for bowel disease and
cancer gene therapy [9-11,27]. This finding suggests that
Bifidobacterium may be a suitable carrier for human
gene expression and secretion in the intestinal tract for
the treatment of gastrointestinal diseases. Here, we
demonstrated the efficacy of BIFN-transformed B.
longum to CVB3-induced myocarditis in the mice. Our
data showed, compared with IFN-transformed B.
longum,t h a tI F N - a2b administered intramuscularly
could reduce significantly virus infection, decrease the
severity of virus-induced myocarditis, and induce a
robust Th1 pattern in the spleen and heart. Neverthe-
less, IFN-transformed B. longum has its own advantages
that include localization in the gastrointestinal cavity
and spread of the physiological role locally [13]. Further
experimentation is needed to evaluate whether IFN-
transformed B. longum can be added to probiotic yogurt
or diet and whether it can protect high-risk people who
eat these products from the virus myocarditis. The
model in this study was to inoculate with CVB3 intra-
peritoneally and this route may affect the therapeutic
efficacy of IFN-transformed B. longum compared with
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peutic roles of IFN-transformed B. longum in virus dis-
eases need to be studied further.
In conclusion, oral administration of IFN-transformed
B. longum can decrease the severity of virus-induced
myocarditis, reduce the virus titers in the heart and
induce a Th1 pattern in the spleen and heart in vivo.
IFN-transformed B. longum may play a potential role in
the treatment of coxsackie virus B3-induced myocarditis.
However, the advantages of the IFN-transformed B.
longum in the treatment and prevention of enterovirus
infection need to be studied further.
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